Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

November 30, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

F-18 THK-5351

Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT02686216 - Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph ) | Biotech Hunter | Biotech Hunter